Advertisement

Bone Marrow Toxicity: White Blood Cells

  • Matti S. Aapro
Chapter

Abstract

Chemotherapy-induced febrile neutropenia (FN) may lead to dose reductions and/or delays that may decrease the chances of curative or life-prolonging treatment in patients with chemo-responsive tumors and is related to increased patient mortality. While often associated with a need for hospitalization, this complication can also be treated in an outpatient setting in low-risk patients. Prophylactic treatment with granulocyte colony-stimulating factors (G-CSFs), such as filgrastim (including approved biosimilars and tbo-filgrastim), lenograstim, or pegfilgrastim and lipegfilgrastim, is available to reduce the risk of chemotherapy-induced neutropenia and its consequences, according to the European Society of Medical Oncology (ESMO) and European Organisation for Research and Treatment of Cancer (EORTC) and other guidelines. Prophylactic G-CSF is recommended in patients receiving a chemotherapy regimen with a risk of FN above 20%. Patient-related risk factors (in particular, older age [≥65 years]) may increase the overall risk of FN and need to be evaluated to decide the use of prophylaxis for regimens with intermediate (10–20%) risk of FN.

Keywords

Granulocyte colony-stimulating factor Filgrastim and tbo-filgrastim Lenograstim Pegfilgrastim Lipegfilgrastim Biosimilars Neutropenia Febrile neutropenia Chemotherapy Guidelines EORTC ESMO 

References

  1. 1.
    Lyman G, Dale D, Wolff DA, Culakova E, Poniewierski MS, Kuderer NM, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28:2914–24.CrossRefPubMedGoogle Scholar
  2. 2.
    Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Cancer Netw. 2008;6:109–18.CrossRefGoogle Scholar
  3. 3.
    Krell D, Jones AL. Impact of effective prevention and management of febrile neutropenia. Br J Cancer. 2009;101(Suppl 1):S23–6.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.CrossRefPubMedGoogle Scholar
  5. 5.
    Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199–212.CrossRefPubMedGoogle Scholar
  6. 6.
    Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(Supplement 5):v111–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51.CrossRefPubMedGoogle Scholar
  8. 8.
    Aapro M, Crawford J, Kamioner D. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer. 2010;18(5):529–41.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99:196–205.CrossRefPubMedGoogle Scholar
  10. 10.
    Touw IP, Bontenbal M. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy? J Natl Cancer Inst. 2007;99:183–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood. 2009;113:3604–11.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353:988–98.CrossRefPubMedGoogle Scholar
  13. 13.
    Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–87.CrossRefPubMedGoogle Scholar
  14. 14.
    Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142:979–95.CrossRefPubMedGoogle Scholar
  15. 15.
    Herbst C, Naumann F, Kruse EB, Monsef I, Bohlius J, Schulz H, et al. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Cochrane Database Syst Rev. 2009;1:CD007107.Google Scholar
  16. 16.
    van de Wetering MD, de Witte MA, Kremer LC, Offringa M, Scholten RJ, Caron HN. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer. 2005;41:1372–82.CrossRefPubMedGoogle Scholar
  17. 17.
    von Minckwitz G, Kummel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, et al. Pegfilgrastim +/− ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19:292–8.CrossRefGoogle Scholar
  18. 18.
    Sternberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, et al. Randomized phase III trial of high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19:2638–46.CrossRefPubMedGoogle Scholar
  19. 19.
    Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5–fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol. 2006;17:1205–12.CrossRefPubMedGoogle Scholar
  20. 20.
    Aapro M, Schwenkglenks M, Lyman GH, Lopez Pousa A, Lawrinson S, Skacel T, et al. Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol. 2010;74:203–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Lyman G, Kuderer N, Crawford J, Wolff DA, Culakova E, Poniewierski MS, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer. 2011;117:1917–27.CrossRefPubMedGoogle Scholar
  22. 22.
    Piedbois P, Serin D, Priou F, et al. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Ann Oncol. 2007;18:52–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma (review). Cochrane Database Syst Rev. 2008;4:CD003189.  https://doi.org/10.1002/14651858.CD003189.pub4.CrossRefGoogle Scholar
  24. 24.
    Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–67.CrossRefPubMedGoogle Scholar
  25. 25.
    Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112:406–11.CrossRefPubMedGoogle Scholar
  26. 26.
    Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23:4198–214.CrossRefPubMedGoogle Scholar
  27. 27.
    Aapro MS. What do prescribers think of biosimilars? Target Oncol. 2012;7(Suppl 1):S51–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract. 2012;18(2):171–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;23:404–11.CrossRefGoogle Scholar
  30. 30.
    Blair HA, Scott LJ. Tbo-Filgrastim: a review in neutropenic conditions. BioDrugs. 2016;30(2):153–60.CrossRefPubMedGoogle Scholar
  31. 31.
    Bond TC, Szabo E, Gabriel S, Klastersky J, Tomey O, Mueller U, Schwartzberg L, Tang B. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J Oncol Pharm Pract. 2017.  https://doi.org/10.1177/1078155217714859. [Epub ahead of print].

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Genolier Cancer CenterClinique de GenolierGenolierSwitzerland

Personalised recommendations